Filing Flows › Theravance Biopharma (TBPH) › Q1 2025
Theravance Biopharma (TBPH) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 12, 2025
Theravance Biopharma (TBPH) reported revenue of $15.4M for the first quarter 2025 (Q1 2025), +6% from a year earlier and -18% from the quarter before. Operating margin was -93.8%, net loss $13.6M (88.2% of revenue).
Theravance Biopharma, Q1 2025: revenue $15.4M (+6% year over year), operating margin -93.8%, net loss $13.6M, operating cash flow $43.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.4M | -18% | +6% |
| Operating profit | −$14.4M | — | — |
| Net earnings | −$13.6M | — | — |
| Operating cash flow | $43.0M | — | — |
What changed
Revenue was $15.4M in Q1 2025, up 6% year over year and down 18% from the previous quarter.
Operating costs exceeded revenue by $14.4M, an operating margin of -93.8%. Total costs grew 16% against revenue growth of 6%. The fastest-growing cost line was Research & development (+28%). The quarter ended with a net loss of $13.6M, narrower than the previous quarter's $15.5M loss.
Operating cash flow was $43.0M. Non-cash charges added back $4.9M of share-based compensation. Working capital and other items added $51.7M.
Questions
What was Theravance Biopharma's revenue in the first quarter 2025?
Theravance Biopharma (TBPH) reported revenue of $15.4M for the first quarter 2025 (Q1 2025), +6% from a year earlier and -18% from the quarter before.
Was Theravance Biopharma profitable in the first quarter 2025?
Operating loss was $14.4M (-93.8% of revenue) and net loss $13.6M.